VanEck Biotech ETF
BBH
87 hedge funds and large institutions have $67.3M invested in VanEck Biotech ETF in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 9 closing their positions.
395% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $265K
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
12% more funds holding
Funds holding: 78 → 87 (+9)
6% more capital invested
Capital invested by funds: $63.7M → $67.3M (+$3.58M)
1.39% less ownership
Funds ownership: 19.61% → 18.22% (-1.4%)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.29M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$664K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$515K |
| 4 |
IAA
Ironsides Asset Advisors
Rocky Mount,
North Carolina
|
+$463K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$450K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.61M |
| 2 |
VF
Virtu Financial
New York
|
-$2.69M |
| 3 |
SFS
Strategic Financial Services
Utica,
New York
|
-$1.23M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$823K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$703K |
BBH Hedge Fund Activity: Q4 2019 in Review
87 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2019, worth a combined $67.3M — up 5.6% from $63.7M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BBH positions and 9 closed out — a net gain of 10 holders — while 17 added to existing stakes and 21 trimmed.
The largest buyer was Jane Street, adding an estimated $1.29M. The largest seller was Citadel Advisors, exiting entirely with an estimated $4.61M sold.
- 87 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2019, up from 78 in Q3 2019.
- Funds reported $67.3M of VanEck Biotech ETF stock for Q4 2019, up 5.6% quarter-over-quarter.
- 19 funds opened new VanEck Biotech ETF positions in Q4 2019 and 9 closed out, a net change of +10 holders.
- The largest VanEck Biotech ETF buyer in Q4 2019 was Jane Street, an estimated $1.29M added.
- The largest VanEck Biotech ETF seller in Q4 2019 was Citadel Advisors, an estimated $4.61M sold.
Based on aggregated 13F filings for Q4 2019.